LAG3 pipeline is 17 deep as first pivotal data near: Data Byte

Data being presented at ASCO will make LAG3 the fourth T cell checkpoint target to demonstrate efficacy in a pivotal trial to treat cancer, behind PD-1, PD-L1 and CTLA-4, and companies are piling in. At least 17 candidates against LAG3 have started clinical trials, and about a third are bispecifics.

At the American Society of Clinical Oncology (ASCO) meeting in June, Bristol Myers Squibb Co. (NYSE:BMY) will present data for the most advanced anti-LAG3 mAb, relatlimab, to treat melanoma. ...